Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : FDA Clearance for Epithelial Thickness Mapping

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/11/2019 | 08:09am EDT

ZEISS Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCT, Enabling More Detailed Assessment of Refractive Surgery Patients.

This new application will be unveiled at the Vision Expo East (VEE) Conference in New York from March 21-24.

ZEISS Medical Technology Segment announced that it has received 510(k) clearance from the FDA for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include Epithelial Thickness Mapping (ETM).

According to refractive specialist Dr. John Doane of Discover Vision Center in Kansas City, the epithelium is the outermost layer of the cornea and is known to actively remodel itself in response to subtle changes in corneal shape due to pathologies such as early keratoconus that may be missed if using corneal topography alone. 'With CIRRUS' Epithelial Thickness Mapping, I can now better identify eligible patients for refractive surgery, and I can also monitor the cornea's post-surgical healing response,' Doane said.

ETM with CIRRUS provides a detailed nine-millimeter map of epithelial thickness that enables more thorough assessment of patients before refractive surgery, allows monitoring of the cornea's response to treatment, and aids in managing patients with ocular surface disorders such as dry eye and progressive corneal diseases such as keratoconus. With ETM, patients can expect a quick, comfortable non-contact exam that takes less than 1-second.

'The addition of this new software is another testament of our continued commitment to providing our customers innovative platforms, so they can provide their patients the highest level of care,' said Jim Mazzo, Global President of Ophthalmic Devices at Carl Zeiss Meditec. 'From early detection to post-operative evaluation, we're here to support to our customers, every step of the way,' he added.

'ZEISS has been at the forefront of industry-defining advancements that have made CIRRUS HD-OCT the industry's standard of care for identifying retinal and glaucoma disease,' said Dr. Ludwin Monz, President, and CEO of Carl Zeiss Meditec. 'This milestone is yet another example to the strength and breadth of our portfolio, expanding CIRRUS' anterior segment capabilities to serve the needs of all eye care professionals.'

ZEISS will showcase the new ETM feature in the latest CIRRUS Software release, along with other flagship products in Booth LP4003 at the Vision Expo East in New York from March 21-24.

ZEISS CIRRUS Epithelial Thickness Mapping Image Download

Contact for the press

Laurie Ferguson

Head of OPT Global Communications

Carl Zeiss Meditec Inc.

Phone: +1 925 560 5163

press.meditec@zeiss.com

Contact for investors

Sebastian Frericks

Director Investor Relations Carl Zeiss Meditec AG

Phone: +49 3641 220-116

Email: investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of EUR1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
07/16INFORMATION PURSUANT : Carl Zeiss Meditec is aiming for the upper end of its rev..
PU
07/15CARL ZEISS MEDITEC : is aiming for the upper end of its revenue forecast for the..
EQ
06/19EUROPE : European stocks tread water, all eyes on Fed
RE
06/18A pivotal month of June
06/04A war on all fronts
06/03CARL ZEISS MEDITEC AG : Release according to Article 40, Section 1 of the WpHG [..
EQ
05/28Workday beats revenue and profit estimates on higher subscriptions
RE
05/14Global trade barriers are affecting markets
05/07A real need to breathe
05/06GLOBAL MARKETS LIVE : Boeing, Berkshire Hathaway, Airbus, Occidental Petroleum…
More news
Financials (EUR)
Sales 2019 1 430 M
EBIT 2019 267 M
Net income 2019 162 M
Finance 2019 658 M
Yield 2019 0,66%
P/E ratio 2019 53,4x
P/E ratio 2020 45,7x
EV / Sales2019 5,62x
EV / Sales2020 5,16x
Capitalization 8 685 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 82,28  €
Last Close Price 97,10  €
Spread / Highest target 2,99%
Spread / Average Target -15,3%
Spread / Lowest Target -48,5%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG42.17%9 785
THERMO FISHER SCIENTIFIC29.51%115 923
DANAHER CORPORATION37.33%101 586
INTUITIVE SURGICAL10.42%61 050
BOSTON SCIENTIFIC CORPORATION19.55%58 755
ILLUMINA-2.24%43 100